Sign Out
Pregnancy: There are no adequate data from the use of fenofibrate in pregnant women. Animal studies have not demonstrated any teratogenic effects. Embryotoxic effects have been shown at doses in the range of maternal toxicity. The potential risk for humans is unknown. Therefore, Fenofibrate 200 mg capsules should only be used during pregnancy after a careful benefit/risk assessment.
Breast-feeding: It is unknown whether fenofibrate and/or its metabolites are excreted in human milk. A risk to the suckling child cannot be excluded. Therefore, fenofibrate should not be used during breast-feeding.
Fertility: Reversible effects on fertility have been observed in animals. There are no clinical data on fertility from the use of Fenofibrate 200 mg capsules.
Continue with Google